I posted this on Raging Bull and Yahoo. I repost it here for any neubee's that don't look at those threads.
Admr, regarding my LTK treatment, I had it done by Dr. Don Johnson, lasereye.com , up near Vancouver, B.C. nearly 5 years ago as I recall. I had worn glasses for 15 years prior to that. I flew up to Vancouver one morning, was treated in both eyes, and returned to California, by myself, in the afternoon. I experienced some discomfort and tearing on the flight back. One Tylenol 3 and antibiotic eyedrops took care of the discomfort. The next day, I still was experiencing a little discomfort. Regular Tylenol, antibiotic drops and sun glasses did the trick.
My vision was extraordinary, much better than with my best glasses or best corrected, as they say. And I could read perfectly as well. I was perfectly corrected in one eye and a little myopic in the other (-.25d). Over approximately the first 3 month my vision changed a little. I needed to start wearing reading glasses. And after several years, a little astigmatism has crept back in but I still do not need glasses to drive.
I should point out that the approval SNRS is seeking does not include astigmatism since early results had limited success. The treatments performed today use the double ring and are even superior to the treatment I had. I know that treatment of astigmatism is feasible with LTK, it is just a matter of perfecting the treatment algorithm.
If I were to be treated again, I might consider monovision. I would want to talk to people with contact lenses that wear that type of correction to get more feedback. Monovision, one eye myopic and the other emmatropic would preclude the need for reading glasses.
I hope we see some more buying opportunities. I think ASCRS will move the stock up a little and announcement of a July panel will push it up further. After ASCRS, I don't think we will see single digit stock prices again.
jpublic89
and in answer to a follow-up, ……….
Admr, I own some BEAM. If you are familiar with previous management, David Muller, Chairman and founder, you would view current management as totally lackluster. The Visx product used to be superior, but maybe not be now with ATCI's technology. Sooner or later, they need to earn some money. I hope you are right on this one.
I also have some KERA which I expect to do well on FDA approval. Also, Keravision might make a good J & J company. Don't like the idea of an implant solving refractive error very well, but then again I don't like the slice and blast of LASIK very well either. Doesn't stop me from investing in this whole sector though. (Staar is out there on the fringe though. If Intacts are a little frightening, intraocular lenses are something only a cataract patient and surgeon could love, not someone with a simple refractive error.) Have several hundred shares of VISX; no point in kicking ourselves over that one, and who knows it still may be a good deal at today's prices. And I have a little LCAV.
But as a patient, I know how huge SNRS is going to be. It is the right procedure for all the baby boomers that now need reading glasses. This population is much, much bigger than the myopia group. LTK will be the procedure of choice; it doesn't cost much, and is minimally invasive. While I have invested in the whole vision care sector, I am very, very heavily weighted in SNRS. I know this is a home run of Visx-like, if not greater, proportion and I know there is a growing number of ophthalmologists of the same opinion.
jpublic89 a.k.a. Joe
|
